Published in J Clin Oncol on September 01, 1989
Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer (1992) 1.84
Isolation and characterization of functional mammary gland stem cells. Cell Prolif (2003) 1.49
Comparative pathology of breast cancer in a randomised trial of screening. Br J Cancer (1991) 1.42
Contribution of p53 to metastasis. Cancer Discov (2014) 1.28
Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Res (2008) 1.26
Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg (1995) 1.24
Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer (2006) 1.15
Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer (2009) 1.14
Correlation between mammographic and sonographic findings and prognostic factors in patients with node-negative invasive breast cancer. Br J Radiol (2010) 1.07
Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. Cancer Prev Res (Phila) (2013) 1.02
A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. Br J Cancer (2011) 1.02
Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Res (2012) 1.00
200 Sentinel lymph node biopsies without axillary lymph node dissection -- no axillary recurrences after a 3-year follow-up. Br J Cancer (2004) 0.99
Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Oncologist (2010) 0.99
Breast cancer treatment and chemoprevention. Can Fam Physician (1999) 0.98
Prognostic and Predictive Factors for Breast Cancer. Breast Cancer (1995) 0.94
Metastasis to sentinel lymph nodes in breast cancer is associated with maturation arrest of dendritic cells and poor co-localization of dendritic cells and CD8+ T cells. Virchows Arch (2011) 0.89
Tumour size and vascular invasion predict distant metastasis in stage I breast cancer. Grade distinguishes early and late metastasis. J Clin Pathol (2005) 0.89
Patterns and risk factors of locoregional recurrence in T1-T2 node negative breast cancer patients treated with mastectomy: implications for postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys (2011) 0.89
Personalized medicine in breast cancer: a systematic review. J Breast Cancer (2012) 0.85
Prediction of axillary lymph node metastasis in primary breast cancer patients using a decision tree-based model. BMC Med Inform Decis Mak (2012) 0.84
Response to treatment of breast cancer. Breast Cancer Res Treat (1991) 0.82
A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer. Oncotarget (2016) 0.81
Prognostic factors and recurrence in breast cancer: experience at the national cancer institute of Mexico. ISRN Oncol (2012) 0.80
Increased Proportion of Variance Explained and Prediction Accuracy of Survival of Breast Cancer Patients with Use of Whole-Genome Multiomic Profiles. Genetics (2016) 0.79
Correlation between conductivity and prognostic factors in invasive breast cancer using magnetic resonance electric properties tomography (MREPT). Eur Radiol (2015) 0.79
Detection of prognostic factors in metastatic breast cancer. J Res Med Sci (2013) 0.78
Prognosis of lymph node-negative breast cancer: Association with clinicopathological factors and tumor associated gene expression. Oncol Lett (2014) 0.78
The presence of sinusoidal CD163(+) macrophages in lymph nodes is associated with favorable nodal status in patients with breast cancer. Virchows Arch (2012) 0.78
Comparison of five different popular scoring systems to predict nonsentinel lymph node status in patients with metastatic sentinel lymph nodes: a tertiary care center experience. Springerplus (2015) 0.77
Understanding the implications of the breast cancer pathology report: a case study. J Adv Pract Oncol (2013) 0.75
Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy? Ther Adv Med Oncol (2009) 0.75
Construction of a database for the evaluation and the clinical management of patients with breast cancer treated with antiestrogens and/or aromatase inhibitors. Clin Cases Miner Bone Metab (2011) 0.75
Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes. Breast Cancer (Dove Med Press) (2015) 0.75
Are two-centimeter breast cancers large or small? Curr Oncol (2013) 0.75
P-cadherin: a useful biomarker for axillary-based breast cancer decisions in the clinical practice. Mod Pathol (2017) 0.75
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol (2001) 11.35
The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med (1999) 6.16
Oligometastases. J Clin Oncol (1995) 4.95
Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med (1994) 4.34
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA (2000) 3.69
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res (2000) 3.42
Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol (1999) 2.97
ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol (2001) 2.87
A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol (1989) 2.71
Radiation therapy of early carcinoma of the breast without mastectomy. Cancer (1980) 2.49
Major hepatic resection using vascular isolation and hypothermic perfusion. Ann Surg (1974) 2.30
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol (1998) 2.26
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol (1996) 2.21
Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol (1997) 2.19
Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst (2001) 2.13
Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst (1995) 2.10
Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys (1979) 2.10
Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer (1993) 2.07
Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst (1998) 2.07
Stopping metastases at their source. N Engl J Med (1997) 2.03
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer (2004) 2.01
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol (2000) 2.00
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol (1997) 1.97
Pathologic predictors of early local recurrence in Stage I and II breast cancer treated by primary radiation therapy. Cancer (1984) 1.95
Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J (2001) 1.93
Breast self-examination and medical examination related to breast cancer stage. Am J Public Health (1981) 1.92
Axillary micro- and macrometastases in breast cancer: prognostic significance of tumor size. Ann Surg (1981) 1.90
The case for and technique of heterotopic liver grafting. Transplant Proc (1979) 1.87
Sarcoma of the breast. A study of 32 patients with reappraisal of classification and therapy. Ann Surg (1985) 1.87
Angiosarcoma and other vascular tumors of the breast. Am J Surg Pathol (1981) 1.86
p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol (1993) 1.85
Hodgkin's disease: evidence for a tumor-associated antigen. N Engl J Med (1971) 1.83
Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol (1993) 1.83
The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol (1991) 1.81
Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. J Clin Oncol (2000) 1.78
Pathogenesis of Hodgkin's disease. Lancet (1972) 1.77
A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res (2001) 1.72
DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. Leukemia (2008) 1.70
Multicentricity and bilaterality in invasive breast carcinoma. Surgery (1982) 1.69
High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res (1998) 1.68
Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res (1998) 1.65
Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol (1986) 1.63
Proliferative capacity of murine hematopoietic stem cells. Proc Natl Acad Sci U S A (1978) 1.62
Predictors of recurrence in stage I (T1N0M0) breast carcinoma. Ann Surg (1981) 1.60
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Paclitaxel-based chemotherapy in carcinoma of the fallopian tube. Gynecol Oncol (2001) 1.59
Spatial and temporal control of gene therapy using ionizing radiation. Nat Med (1995) 1.59
Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. J Clin Oncol (1995) 1.59
Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res (2000) 1.55
Prostate-specific antigen levels in African-Americans correlate with insurance status as an indicator of socioeconomic status. Cancer J Sci Am (2006) 1.54
Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. Gynecol Oncol (1995) 1.54
Discontinuous or "skip" metastases in breast carcinoma. Analysis of 1228 axillary dissections. Ann Surg (1983) 1.53
Considerations in the radiation therapy of Wilms' tumor. Cancer (1973) 1.51
Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol (1993) 1.50
Race and the Will Rogers phenomenon in prostate cancer. Cancer J Sci Am (1998) 1.50
Pharyngeal reflux after gastric pull-up esophagectomy with neck and chest anastomoses. J Thorac Cardiovasc Surg (1999) 1.48
Breast cancer metastatic phenotype as predicted by histologic tumor markers. Cancer J Sci Am (1997) 1.48
Limited surgery and radiotherapy for early breast cancer. N Engl J Med (1985) 1.48
Definition of histopathologic changes in gastroesophageal reflux disease. Am J Surg Pathol (2000) 1.47
Peritoneal cytology as an indicator of disease in patients with residual ovarian carcinoma. Obstet Gynecol (1988) 1.45
Loss of hematopoietic stem cell self-renewal after bone marrow transplantation. Blood (1989) 1.45
Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst (2000) 1.45
Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res (1998) 1.45
Serum erythropoietin titers in patients with human immunodeficiency virus (HIV) infection and anemia. J Acquir Immune Defic Syndr (1991) 1.45
Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst (1997) 1.45
It's too soon to know. J Natl Cancer Inst (1990) 1.42
Observation of a centrality-dependent dijet asymmetry in lead-lead collisions at sqrt[S(NN)] =2.76 TeV with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.41
Association between initial diagnostic procedure and hysteroscopy and abnormal peritoneal washings in patients with endometrial carcinoma. Cancer (2000) 1.41
Comparative study of infectious complications of different types of chronic central venous access devices. Cancer (1994) 1.41
Effects of noise and noise suppression on speech perception by cochlear implant users. Ear Hear (1992) 1.40
The benefits of mammography are not limited to women of ages older than 50 years. Cancer (1998) 1.39
The key and the lamppost. J Clin Oncol (1999) 1.39
Advances in radiation oncology. Lancet (1997) 1.39
Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol (1989) 1.39
Measurement of dijet azimuthal decorrelations in pp collisions at sqrt(s)=7 TeV. Phys Rev Lett (2011) 1.39
A piece of my mind. Tales of the unnatural: return from the dean(d) JAMA (1998) 1.38
Evidence for structured variation in self-renewal capacity within long-term bone marrow cultures. Proc Natl Acad Sci U S A (1980) 1.38
Indications for lower urinary tract reconstruction in women after cystectomy for bladder cancer: a pathological review of female cystectomy specimens. J Urol (1995) 1.38
Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J Urol (1996) 1.37
p53 and treatment of bladder cancer. Nature (1997) 1.36
The first century of cancer chemotherapy. J Clin Oncol (1998) 1.35
Determination of the strange-quark density of the proton from ATLAS measurements of the W→ℓν and Z→ℓℓ cross sections. Phys Rev Lett (2012) 1.34
Male breast cancer: a clinicopathologic study of 97 cases. Ann Surg (1978) 1.34
Contralateral breast carcinoma: an assessment of risk and prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20-year follow-up. Surgery (1989) 1.34
Estrogen receptor protein in breast cancer as a predictor of recurrence. Cancer (1981) 1.33
p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res (1998) 1.32
Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.32
Radiation therapy as initial treatment for early stage cancer of the breast without mastectomy. Cancer (1977) 1.29
Follicular lesions of thyroid: a 5-year fine-needle aspiration experience. Cancer (2000) 1.28
Secretory carcinoma of the breast. Arch Pathol Lab Med (1991) 1.28
Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst (1998) 1.28